The effects of preeclampsia on signaling to hematopoietic progenitor cells

Donna A. Santillan, PhD,1 Wendy Hamilton,1 Ashley Christensen,3 Katelyn Talcott,3 Lindsay Gravatt,1 Mark K. Santillan, MD,2 Stephen K. Hunter, MD PhD2

Keywords: pre-eclampsia, hematopoiesis, placenta, pregnancy, signal transduction

Abstract

Background: The role of the microenvironment is important in cell differentiation. The effect of placental disease on the growth and differentiation and hematopoietic stem cells has not been well-studied.

Methods: Enzyme linked immunoassay was used to measure erythropoietin and osteopontin in plasma from umbilical cord blood of children born to normotensive and preeclamptic women. Additionally, CD34+ cells were isolated from umbilical cord blood and grown in complete methylcellulose media. Colony types were identified and enumerated.

Results: Differences in the concentration of erythropoietin in the cord blood between the controls and the preeclamptics approached significance (P = 0.067) using a Mann-Whitney U test. In the plasma of cord blood from children born to normotensive women, the median erythropoietin was 0.186 mIU/mL compared to 1.986 mIU/mL in children of preeclamptic women. We did not find any significant differences in the number and types of colonies; however, there was a trend toward increased BFU-E in the preeclamptic samples. Furthermore, this trend for increased BFU-E colonies was also seen from CD34+ cells isolated from umbilical cord blood of severe preeclamptics compared to mild.

Conclusion: Our preliminary studies suggest that abnormalities in the placenta, such as those found when the mother experiences preeclampsia, may affect the ability of hematopoietic stem cells to grow and differentiate.

1Division of Reproductive Science Research, and 2Division of Maternal Fetal Medicine, The Department of Obstetrics and Gynecology, 3Roy J. and Lucille A. Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA.

Background

The regulation of the growth and differentiation of hematopoietic stem cells during development is quite complex. The role of the placenta in hematopoiesis is not yet well understood. Although the placenta has been shown to be a site of definitive hematopoiesis, it is unclear what impact placental disease has on hematopoietic stem cells and if there are any short or long-term ramifications to the child. To begin to address this question, we have measured cytokines from the umbilical
Effects of preeclampsia on differentiation

cord blood of pregnancies with a normal placenta in comparison to an abnormal placenta. As placental insufficiencies are well described in preeclampsia, we have used this disease as our model of an abnormal placenta in our study of cytokines and cell growth.

Cytokines, growth factors, and chemokines are all well-known regulators of hematopoiesis. However, in vitro hematopoietic stem cell differentiation and expansion experiments demonstrate that there are other, less-well understood factors that also exert control of cell growth and differentiation. The in vivo cellular microenvironment may provide a critical influence over the cells. This microenvironment can be altered in the face of pregnancy-related diseases, such as preeclampsia. Preeclampsia is a disease of pregnancy in which parturients develop hypertension, proteinuria, and potential seizures, liver and kidney failure.

In preeclampsia, there are significant abnormalities in the placenta such as abnormal cytotrophoblast differentiation, shallow trophoblast invasion, and decreased blood flow to and from the placenta. Multiple studies of preeclampsia have found increased apoptosis in cytotrophoblasts. Kadyrov confirmed an increased rate of apoptosis in trophoblast cells of spiral artery walls. Since spiral arteries are of maternal origin, it is likely that a maternal signal is promoting the apoptosis. The apoptotic signal may come from maternal macrophages near the spiral arteries. Large numbers of macrophages were seen in vessel cross-sections from preeclamptic women; however, macrophages were rare in sections from normal pregnancies. Furthermore, necrosis may occur as a result of aberrant trophoblast cell differentiation. Such necrosis of trophoblasts results in the release of cell fragments into the maternal bloodstream. These fragments are readily detected in preeclamptic maternal peripheral blood and may trigger an inflammatory response.

Several studies point to differences in hematopoietic cell populations observed in children born to preeclamptic and normotensive mothers. Using flow cytometry, Surbek et al. demonstrated that the fetal cord blood of preeclamptic women contained fewer CD34+ positive cells (p=0.023) compared to the control group. In addition, they found that samples from preeclamptic patients produced fewer colony forming units in erythropoietin and mixed growth factor–stimulated in vitro differentiation assays. A study by Stallmach et al. found less erythroid precursors and early granulopoietic cells in fetal livers of preeclamptic affected pregnancies. There is not a clear understanding of whether there are altered signaling mechanisms affecting fetal hematopoiesis in preeclampsia. Several possibilities exist including differences in cytokines and growth factors that can affect the growth and differentiation potential of cells. A recent study found significantly higher levels of leukemia inhibitory factor in placentas of preeclamptic women compared to well-matched normotensive controls. Additionally, differences in osteopontin localization have been demonstrated in preeclamptic placentas. As osteopontin has biological functions in
cell survival, angiogenesis, and immune function, aberrant localization may have secondary effects on cells in their microenvironment.

Another potential mechanism affecting fetal hematopoiesis, demonstrated in mice, involves the placenta as a hematopoietic organ. Because there is incomplete placentation in preeclampsia, this may contribute to the observed differences by leading to a reduced number of hematopoietic progenitors. A reduction in the number of hematopoietic progenitors may be responsible for the decrease in CD3+, CD4+, and CD8+CD28+ lymphocytes that has been observed in neonates born to mothers with severe preeclampsia.

In this preliminary investigation, our objective was to determine if any functional differences exist in signaling by analyzing the in vitro differentiation potential of hematopoietic progenitors isolated from umbilical cord blood from babies born to women with preeclampsia compared to those born to normotensive women. In addition, we sought to identify differences in cytokines in the cord blood samples.

**Methods**

**Study subjects and sample collection**

Patient specimens were obtained through user agreements with the Institutional Review Board – approved Hematopoietic Stem Cell Bank and the Maternal Fetal Tissue Bank at the University of Iowa. Umbilical cord blood samples were collected from 15 women with mild and severe preeclampsia that delivered at term (>37 weeks). The diagnosis of mild preeclampsia is made when a pregnant woman has a persistent blood pressure of 140 mm Hg systolic or higher or 90 mm Hg diastolic or higher that occurs after 20 weeks of gestation on 2 occasions 6 hours apart in a woman with previously normal blood pressures and proteinuria, defined as urinary excretion of 0.3 g protein or higher in a 24-hour urine specimen. Severe preeclampsia is defined by a systolic blood pressure >160 mm Hg or a diastolic blood pressure >110 mm Hg on at least 2 occasions >6 hours apart and 3-4+ proteinuria, or HELLP syndrome (severe preeclampsia with hemolysis, elevated liver enzymes, and low platelet count). Samples from a control group of 18 women with normal pregnancies were also obtained. Exclusion criteria included maternal chronic hypertension, known preexisting microvascular disease, and diabetes mellitus. Exclusion criteria of the Hematopoietic Stem Cell Bank and the Maternal Fetal Tissue Bank are maternal age less than 18 years old, HIV+, Hepatitis C+, inability to provide informed consent, and non-English speaking.

**Plasma Isolation**

Cord blood was collected as described above. Plasma was isolated using a Plasma Separator Tube (Becton Dickinson) per the manufacturer’s recommendations. Plasma was immediately aliquoted, snap frozen, and stored at -80 °C until analysis.

**Cytokine Analysis**

Erythropoietin (EPO) and osteopontin (OPN) in the plasma of umbilical cord blood were analyzed using a
commercially available ELISA assays (Platinum assays from eBioscience). All samples were analyzed in duplicate and the average of the samples was used to calculate the EPO and OPN concentrations. Manufacturer’s protocols were followed for these assays.

**Cell Isolation and culture**

Cord blood was collected at delivery into Citrate Phosphate Dextrose Solution (Fenwal Technologies). CD34+ cells were isolated by immunomagnetic selection (StemSep, Stem Cell Technologies) from freshly collected umbilical cord blood from a subset of patients (8 Preeclamptics, 5 normotensive women). 500 cells from each sample were plated in duplicate in complete methylcellulose media (Methocult, Stem Cell Technologies) and incubated for 16 days at 37°C in 5% CO₂. Colonies were identified and enumerated by visual inspection. Colony types that are expected to arise in this assay include colony-forming unit-erythroid (CFU-E), burst forming unit-erythroid (BFU-E), colony forming unit-granulocyte, macrophage (CFU-GM), and colony forming unit-granulocyte, erythroid, macrophage, megakaryocyte (CFU-GEMM).

**Statistical Analysis**

All statistical analyses were performed with SigmaStat 3.0 software (Systat Software, Inc, California). Descriptive statistics were used to characterize the data. In addition, the Fisher exact test was utilized for dichotomous variables. For continuous variables, the 2-tailed t test or if criteria for normality were not met, the non-parametric Mann-Whitney U test was utilized. All variables were tested at significance level of 0.05.

**Table 1. Maternal Demographics**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Control (mean or median) N=18</th>
<th>Preeclamptic (mean or median) N=15</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>29.9</td>
<td>28.6</td>
<td>0.26a</td>
</tr>
<tr>
<td>BMI</td>
<td>29.1</td>
<td>33.7</td>
<td>0.10a</td>
</tr>
<tr>
<td>Gravida</td>
<td>2</td>
<td>2</td>
<td>0.97b</td>
</tr>
<tr>
<td>% Caucasian</td>
<td>88.9%</td>
<td>93.8%</td>
<td>1.0c</td>
</tr>
</tbody>
</table>

*a2-tailed t test  
bMann Whitney U  
cFisher Exact Test

**Results**

We began our studies by examining differences in cytokine signaling between the preeclamptic and normotensive cord blood (N=15 and N=18, respectively). Table 1 demonstrates that there were no significant differences in the age, body mass index, gravida, or percentage of Caucasians between these two groups of patients. In analyzing characteristics of their pregnancies, no differences were found in the percentage of multiples, GBS positive, diabetics, the gestational age at delivery, the rate of cesarean section, or birthweight. From these very similar groups, differences in the concentration of erythropoietin in the cord blood between the controls and the preeclamptics approached significance (P = 0.067) in a Mann-Whitney U. In the plasma of cord blood from children born to normotensive women, the median EPO was 0.186 mIU/mL compared to 1.986 mIU/mL in children of preeclamptic women (Figure 1).
Effects of preeclampsia on differentiation

Figure 1. Erythropoietin concentration in umbilical cord blood plasma.

One marker of fetal well-being at birth is the Apgar score. Because there was a significant difference in the 1 min Apgar between groups (Table 2), we were also interested in whether there was in a difference in osteopontin concentrations in the cord blood samples between groups. Maternal plasma osteopontin has shown to be altered in women with preeclampsia who have extensive endothelial damage.\textsuperscript{15} We wanted to determine whether these differences are also found in the plasma of umbilical cord blood. Interestingly, we found a statistically significant increase in the concentration of osteopontin in the plasma ofumbilical cord blood of children born to preeclamptic women compared to those born to normotensive women (44.65±2.5ng/ml versus 35.96±2.59ng/ml \( P = 0.022 \)) (Figure 2). As osteopontin is also an inhibitor of hematopoietic stem cells,\textsuperscript{16} we were also interested in whether differences in colony sizes could be attributed to differences in osteopontin.

Table 2. Pregnancy Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Control (%) or mean</th>
<th>Preeclamptic (%) or mean</th>
<th>( P ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multiples</td>
<td>11.1</td>
<td>18.8</td>
<td>0.26\textsuperscript{a}</td>
</tr>
<tr>
<td>GBS positive</td>
<td>41.2</td>
<td>14.3</td>
<td>0.13\textsuperscript{a}</td>
</tr>
<tr>
<td>Diabetes</td>
<td>5.9</td>
<td>6.7</td>
<td>1.0\textsuperscript{a}</td>
</tr>
<tr>
<td>Gestational Age at Delivery</td>
<td>37 2/7 weeks</td>
<td>36 6/7 weeks</td>
<td>0.54\textsuperscript{b}</td>
</tr>
<tr>
<td>C-Section</td>
<td>44.4%</td>
<td>53.3%</td>
<td>0.874\textsuperscript{a}</td>
</tr>
<tr>
<td>Birthweight (grams)</td>
<td>2921.2</td>
<td>2913.7</td>
<td>0.98\textsuperscript{b}</td>
</tr>
<tr>
<td>1 min APGAR</td>
<td>9</td>
<td>8</td>
<td>0.002\textsuperscript{c}</td>
</tr>
</tbody>
</table>

\textsuperscript{a}2-tailed \( t \) test \\
\textsuperscript{b}Mann Whitney U \\
\textsuperscript{c}Fisher Exact Test

As other groups have reported a difference in erythropoietin and we saw a trend toward an increase in EPO in preeclampsics, we sought to determine whether in a subset of preeclamptic and normotensive patients if there was a difference in the differentiation potential of the umbilical cord stem cells when grown in methylcellulose in complete medium with identical cytokine concentrations. We did not find any significant differences in the number and types of colonies; however, there was a
trend toward increased BFU-E in the preeclamptic samples (Figure 3). Furthermore, this trend for increased BFU-E colonies was also seen from CD34+ cells isolated from umbilical cord blood of severe preeclamptics compared to mild (Figure 4). More subjectively, colonies of all types were consistently found to be smaller in size in the colony assay of the preeclamptic samples (Figure 5).

![Figure 2. Osteopontin concentration in umbilical cord blood plasma. *2-tailed t test P = 0.02 vs. control.](image)

As an equal number of cells were plated per sample, differences in colony count were not due to initial cell number. However, as other groups have found a difference in the number of hematopoietic progenitors and cord volume collected between samples from preeclamptic and normotensive mothers, we also addressed this question. No significant differences were found in the number of CD34+ cells collected or in the volume of cord blood collected. As shown in Table 3, the average total number of CD34+ cells was $4.7 \times 10^5$ from normotensive pregnancies compared to $5.5 \times 10^5$ from preeclamptic pregnancies ($P = 0.80$). The average volume of cord blood collected was 99.6ml in normotensive pregnancies and 75.8ml in preeclamptic pregnancies ($P = 0.15$).
Effects of preeclampsia on differentiation

Discussion

The fairly recent identification of the placenta as a site of definitive hematopoiesis raises many intriguing questions, including what are the effects of placental disease on the hematopoietic stem cells that arise there and whether this leads to any effects on the child. To begin to address these questions, we sought to understand whether there were differences in cytokine signals for cell growth and differentiation and whether hematopoietic stem cells isolated from the umbilical cord of children born to normotensive and preeclamptic women had any differences in differentiation potential in vitro.

One of the most well-defined mechanisms to alter cell differentiation is through cytokine signaling. In the case of erythroid cells, erythropoietin (EPO) is critically important. Therefore, we began our investigation by measuring EPO. Unlike other studies, we did not detect a statistically significant difference in EPO, although we did identify a trend toward increased EPO in cord blood of children born to preeclamptic women (Figure 1). Our results may not have reached significance because of the smaller sample size in our study compared to others. Our result suggests that it is unlikely that increased EPO alone is driving progenitor cells into erythroid cells. Given the role of osteopontin in regulating stem cell expansion and its elevation in preeclamptics women with extensive endothelial damage, we also measured OPN in the plasma of our umbilical cord blood samples. Interestingly, while OPN was not different in the maternal plasma of...
normotensive and preeclamptics by others, we found an increase in the plasma of cord blood of preeclamptics without regard to the severity of the preeclampsia. Therefore, this increase in OPN in cord blood plasma may be a reflection of the suppression of the stem cells rather than of endothelial damage in the child.

**Figure 4. Comparison of in vitro differentiation of CD34+ cells** from the umbilical cord blood of mild (dark red bars) and severe preeclamptics (blue bars).

**Figure 5. Colonies from preeclamptic samples appeared smaller in the colony assay.**
Table 3. Sample Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Control</th>
<th>Preeclamptic</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average cord blood volume collected</td>
<td>99.6ml</td>
<td>75.8ml</td>
<td>0.15a</td>
</tr>
<tr>
<td>Average number of CD34+ cells isolated</td>
<td>4.7 x 10^5</td>
<td>5.5 x 10^5</td>
<td>0.75a</td>
</tr>
</tbody>
</table>

Although there tended to be more erythroid precursors from the severe preeclamptic samples compared to the mild preeclamptic samples, the difference was not statistically significant. To clarify if the CD34+ cells isolated from the cord blood of preeclamptic and normotensive women would form the same colonies in vitro under conditions in identical growth media for cells, we began by analyzing umbilical cord blood to determine if there is a difference; however, this sample would contain hematopoietic stem cells generated by all sites of definitive hematopoiesis. As others have described differences in the cord blood cells of preeclamptics, we wanted to begin our investigation with these cells.7,14,18 Given that with this mixed population we began to see differences in colonies, it would be interesting to isolate hematopoietic stem cells from placental tissue and to determine if this pool of cells specifically has an aberrant differentiation and growth potential in diseased placenta, such as in preeclampsia. Additionally, it would be informative to perform the colony assay under hypoxic conditions to determine if low oxygen conditions affect the differentiation potential of the CD34+ cells.

While not statistically significant, the trend toward an increased propensity to differentiate into erythroid precursors in cases of severe preeclampsia is interesting. In preeclampsia, the placenta is in a hypoxic state due to incomplete remodeling of the spiral arteries. We hypothesize that cells are primed to differentiate into erythroid cells to compensate for the hypoxia. Future studies will further explore this hypothesis.

Acknowledgements: This work was supported by the Department of Obstetrics & Gynecology at the University of Iowa Hospitals & Clinics.

References


